DGAP-News: Biotest AG / Key word(s): Regulatory Approval
24.01.2019 / 07:00
The issuer is solely responsible for the content of this announcement.
Biotest receives Intratect(R) approval for additional indications in 22 European countries
– Additional fields of use in neurology (CIDP, MMN) and secondary immunodeficiencies (SID)
– 40% of the globally produced immunoglobulins are used in the treatment of these diseases
– Biotest plans to enter new markets
Dreieich, 24 January 2019. Biotest has received the extension of the approved indications of Intratect(R) for the neurological indications chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), as well as an extension in the field of secondary immunodeficiencies (SID).
CIDP is globally the most important neurological indication in immunoglobulin therapy – approximately 25% of the world’s standard immunoglobulins are administered to treat CIDP. To date, Intratect(R) has been used very successfully for the treatment of acute neurological disorders such as Guillian-Barré syndrome (GBS).
Another application field of Intratect(R) are the primary and secondary immunodeficiency diseases (PID, SID). Reasons for the development of SIDs include various cancers, side effects of immunosuppressive drugs or metabolic disorders. At least 15% of the world’s immunoglobulin levels are prescribed in the area of secondary immunodeficiencies. The label extension eliminates previous limitations of Intratect(R) approval.
With the broader range of indications, Biotest plans to enter new markets to enable additional patients to receive immunoglobulin therapy with Intratect(R).
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
24.01.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|